TrialJournal of Parkinson's disease2021

Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson's Disease: A Randomized, Placebo-Controlled, Phase 1 Study.

Werner Poewe et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.